These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


Pubmed for Handhelds

PUBMED FOR HANDHELDS

Journal Abstract Search

264 related items for PubMed ID: 8651941

  • 1. Regulation of phosphorylation of deoxycytidine and 2',2'-difluorodeoxycytidine (gemcitabine); effects of cytidine 5'-triphosphate and uridine 5'-triphosphate in relation to chemosensitivity for 2',2'-difluorodeoxycytidine.
    van Haperen VW, Veerman G, Vermorken JB, Pinedo HM, Peters G.
    Biochem Pharmacol; 1996 Apr 12; 51(7):911-8. PubMed ID: 8651941
    [Abstract] [Full Text] [Related]

  • 2. Schedule dependence of sensitivity to 2',2'-difluorodeoxycytidine (Gemcitabine) in relation to accumulation and retention of its triphosphate in solid tumour cell lines and solid tumours.
    Ruiz van Haperen VW, Veerman G, Boven E, Noordhuis P, Vermorken JB, Peters GJ.
    Biochem Pharmacol; 1994 Oct 07; 48(7):1327-39. PubMed ID: 7945430
    [Abstract] [Full Text] [Related]

  • 3. Collateral sensitivity to gemcitabine (2',2'-difluorodeoxycytidine) and cytosine arabinoside of daunorubicin- and VM-26-resistant variants of human small cell lung cancer cell lines.
    Bergman AM, Munch-Petersen B, Jensen PB, Sehested M, Veerman G, Voorn DA, Smid K, Pinedo HM, Peters GJ.
    Biochem Pharmacol; 2001 Jun 01; 61(11):1401-8. PubMed ID: 11331076
    [Abstract] [Full Text] [Related]

  • 4. Induction of resistance to 2',2'-difluorodeoxycytidine in the human ovarian cancer cell line A2780.
    Ruiz van Haperen VW, Veerman G, Eriksson S, Stegmann AP, Peters GJ.
    Semin Oncol; 1995 Aug 01; 22(4 Suppl 11):35-41. PubMed ID: 7481843
    [Abstract] [Full Text] [Related]

  • 5. Deoxycytidine kinase and deoxycytidine deaminase activities in human tumour xenografts.
    Ruiz van Haperen VW, Veerman G, Braakhuis BJ, Vermorken JB, Boven E, Leyva A, Peters GJ.
    Eur J Cancer; 1993 Aug 01; 29A(15):2132-7. PubMed ID: 8297652
    [Abstract] [Full Text] [Related]

  • 6. Decreased resistance to gemcitabine (2',2'-difluorodeoxycitidine) of cytosine arabinoside-resistant myeloblastic murine and rat leukemia cell lines: role of altered activity and substrate specificity of deoxycytidine kinase.
    Bergman AM, Pinedo HM, Jongsma AP, Brouwer M, Ruiz van Haperen VW, Veerman G, Leyva A, Eriksson S, Peters GJ.
    Biochem Pharmacol; 1999 Feb 15; 57(4):397-406. PubMed ID: 9933028
    [Abstract] [Full Text] [Related]

  • 7. Cytotoxic activity of 2',2'-difluorodeoxycytidine, 5-aza-2'-deoxycytidine and cytosine arabinoside in cells transduced with deoxycytidine kinase gene.
    Beauséjour CM, Gagnon J, Primeau M, Momparler RL.
    Biochem Biophys Res Commun; 2002 May 24; 293(5):1478-84. PubMed ID: 12054682
    [Abstract] [Full Text] [Related]

  • 8. Kinetic studies on 2',2'-difluorodeoxycytidine (Gemcitabine) with purified human deoxycytidine kinase and cytidine deaminase.
    Bouffard DY, Laliberté J, Momparler RL.
    Biochem Pharmacol; 1993 May 05; 45(9):1857-61. PubMed ID: 8494545
    [Abstract] [Full Text] [Related]

  • 9. Differential effects of gemcitabine on ribonucleotide pools of twenty-one solid tumour and leukaemia cell lines.
    van Moorsel CJ, Bergman AM, Veerman G, Voorn DA, Ruiz van Haperen VW, Kroep JR, Pinedo HM, Peters GJ.
    Biochim Biophys Acta; 2000 Mar 06; 1474(1):5-12. PubMed ID: 10699484
    [Abstract] [Full Text] [Related]

  • 10. Nucleotide specificity of human deoxycytidine kinase.
    Shewach DS, Reynolds KK, Hertel L.
    Mol Pharmacol; 1992 Sep 06; 42(3):518-24. PubMed ID: 1406603
    [Abstract] [Full Text] [Related]

  • 11. Pharmacogenomics of gemcitabine metabolism: functional analysis of genetic variants in cytidine deaminase and deoxycytidine kinase.
    Baker JA, Wickremsinhe ER, Li CH, Oluyedun OA, Dantzig AH, Hall SD, Qian YW, Ring BJ, Wrighton SA, Guo Y.
    Drug Metab Dispos; 2013 Mar 06; 41(3):541-5. PubMed ID: 23230131
    [Abstract] [Full Text] [Related]

  • 12. Detection of an alternatively spliced form of deoxycytidine kinase mRNA in the 2'-2'-difluorodeoxycytidine (gemcitabine)-resistant human ovarian cancer cell line AG6000.
    Al-Madhoun AS, van der Wilt CL, Loves WJ, Padron JM, Eriksson S, Talianidis I, Peters GJ.
    Biochem Pharmacol; 2004 Aug 15; 68(4):601-9. PubMed ID: 15276067
    [Abstract] [Full Text] [Related]

  • 13. Gemcitabine: a modulator of intracellular nucleotide and deoxynucleotide metabolism.
    Heinemann V, Schulz L, Issels RD, Plunkett W.
    Semin Oncol; 1995 Aug 15; 22(4 Suppl 11):11-8. PubMed ID: 7481839
    [Abstract] [Full Text] [Related]

  • 14. Comparison of the cellular pharmacokinetics and toxicity of 2',2'-difluorodeoxycytidine and 1-beta-D-arabinofuranosylcytosine.
    Heinemann V, Hertel LW, Grindey GB, Plunkett W.
    Cancer Res; 1988 Jul 15; 48(14):4024-31. PubMed ID: 3383195
    [Abstract] [Full Text] [Related]

  • 15. The relation between deoxycytidine kinase activity and the radiosensitising effect of gemcitabine in eight different human tumour cell lines.
    Pauwels B, Korst AE, Pattyn GG, Lambrechts HA, Kamphuis JA, De Pooter CM, Peters GJ, Lardon F, Vermorken JB.
    BMC Cancer; 2006 May 30; 6():142. PubMed ID: 16734894
    [Abstract] [Full Text] [Related]

  • 16. Cyclopentenyl cytosine-induced activation of deoxycytidine kinase increases gemcitabine anabolism and cytotoxicity in neuroblastoma.
    Bierau J, van Gennip AH, Leen R, Meinsma R, Caron HN, van Kuilenburg AB.
    Cancer Chemother Pharmacol; 2006 Jan 30; 57(1):105-13. PubMed ID: 16133534
    [Abstract] [Full Text] [Related]

  • 17. Cross-resistance in the 2',2'-difluorodeoxycytidine (gemcitabine)-resistant human ovarian cancer cell line AG6000 to standard and investigational drugs.
    Bergman AM, Giaccone G, van Moorsel CJ, Mauritz R, Noordhuis P, Pinedo HM, Peters GJ.
    Eur J Cancer; 2000 Oct 30; 36(15):1974-83. PubMed ID: 11000580
    [Abstract] [Full Text] [Related]

  • 18. The deaminated metabolite of gemcitabine, 2',2'-difluorodeoxyuridine, modulates the rate of gemcitabine transport and intracellular phosphorylation via deoxycytidine kinase.
    Hodge LS, Taub ME, Tracy TS.
    Drug Metab Dispos; 2011 Nov 30; 39(11):2013-6. PubMed ID: 21832002
    [Abstract] [Full Text] [Related]

  • 19. Role of deoxycytidine kinase (dCK) activity in gemcitabine's radioenhancement in mice and human cell lines in vitro.
    Grégoire V, Rosier JF, De Bast M, Bruniaux M, De Coster B, Octave-Prignot M, Scalliet P.
    Radiother Oncol; 2002 Jun 30; 63(3):329-38. PubMed ID: 12142097
    [Abstract] [Full Text] [Related]

  • 20. Cellular elimination of 2',2'-difluorodeoxycytidine 5'-triphosphate: a mechanism of self-potentiation.
    Heinemann V, Xu YZ, Chubb S, Sen A, Hertel LW, Grindey GB, Plunkett W.
    Cancer Res; 1992 Feb 01; 52(3):533-9. PubMed ID: 1732039
    [Abstract] [Full Text] [Related]

    Page: [Next] [New Search]
    of 14.